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Abstract
Background: Circulating lipid metabolites are associated with many physiological and biological processes in the
body, and therefore could be used as biomarkers for evaluating drug efficacy and safety in preclinical studies. However,
differences in circulating lipid profiles among humans and animals often used in preclinical studies have not been fully
investigated.
Methods: We performed lipidomic analysis to obtain circulating lipid profiles of fasted humans (Caucasian, n = 15) and
three animal species used in preclinical studies (mice [BALB/c, n = 5], rats [Sprague–Dawley, n = 5], and rabbits
[New Zealand White, n = 5]) by using liquid chromatography-mass spectrometry.
Results: Our data showed marked differences in lipid profiles among humans and these animal species.
Furthermore, we observed that the levels of many lipid metabolites, such as poly-unsaturated fatty acid-containing
cholesteryl esters, ether-type phosphoglycerolipids, and sulfatides, were significantly different (p < 0.05) by more than
10-fold in these animals (depending on the animal species) from humans.
Conclusion: Our data could be useful while extrapolating the data on the biomarker candidates identified in
preclinical studies into clinical studies.
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Background
Lipid metabolites, such as phosphoglycerolipids (PLs)
and sphingolipids (SLs), are components of the cell
membrane, and play key roles in a variety of physio-
logical and biological processes including apoptosis [1]
and autophagy [2]. These lipid metabolites are also the
major components of plasma lipoproteins, including
low- and high-density lipoproteins. Because somatic tissues
uptake and/or excrete lipid metabolites through lipopro-
teins, the levels of circulating lipid metabolites are closely
related to the levels of lipid metabolites in tissues [3]. Thus,
circulating lipid metabolites might be associated with many
physiological and biological processes in the whole body,
and therefore might help in selecting useful biomarkers for
evaluating diseased states and drug responses.
Lipidomics is a metabolomics approach focused on
lipid metabolites [4, 5] that can overview the lipid profile
of biofluids and tissues, and hence is used as a high-
throughput tool for simultaneously identifying various
biomarker candidates. So far, lipidomics has already been
applied not only in clinical studies [6–8], but also in pre-
clinical pharmacology and toxicology studies [9–13].
This is because circulating lipid metabolites are common
among animals used in preclinical studies and humans,
and thus can be used to simplify the extrapolation of
data on biomarkers identified in preclinical studies into
clinical studies. However, differences in circulating lipid
profiles among humans and animals used in preclinical
studies have not been fully investigated.
In the present study, we employed lipidomic analysis
to obtain circulating lipid profiles of humans (Caucasian,
n = 15) and three animal species used in preclinical stud-
ies (mice [BALB/c, n = 5], rats [Sprague–Dawley, n = 5],
and rabbits [New Zealand White, n = 5]) by using liquid
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chromatography-mass spectrometry (LC-MS). To minimize
gender and age-associated variation affecting the differences
in lipid metabolites, we selected young adult males which
are generally used in the preclinical and phase I studies.
We observed marked differences in lipid profiles between
humans and all the selected animal species. In addition, our
data showed that the levels of many lipid metabolites, such
as poly-unsaturated fatty acid (PUFA)-containing choles-
teryl esters (ChEs), ether-type PLs and sulfatides (Suls), are
more than 10-fold higher in the selected animals
(depending on the animal species) than in humans.
These findings would provide useful fundamental infor-
mation for selecting biomarker candidates obtained/iden-




Blood samples from healthy white males were purchased
from PromedDX (Norton, MA). The ethics committee
of the National Institute of Health Sciences authorized
PromedDX as a validated provider of blood samples and
exempted us from the committee’s approval for use of the
purchased blood samples. The samples were collected after
obtaining written informed consent from all human sub-
jects; the subjects were 15 young men (25-33-years-old)
who had been fasting for more than 14 h. Fresh blood from
each individual was collected and simultaneously drawn
into 10 ml Vacutainer Plasma Separator Tubes containing
EDTA (Becton Dickinson, Franklin Lakes, NJ), which is
needed for plasma separation. Plasma was separated within
2 h after the collection of blood samples. The plasma sam-
ples were immediately frozen and stored at −80 °C. After
shipment with dry ice from PromedDX, all frozen samples
were thawed once on ice and divided into small aliquots
before storing at −80 °C until lipid extraction.
Animal plasma
Plasma samples of male BALB/c mice (n = 5, 10-weeks-old)
and male New Zealand white rabbits (n = 5, 10-weeks-old)
were purchased from KOHJIN BIO (Saitama, Japan). The
plasma sample of male Sprague–Dawley rats (n = 5,
8-weeks-old; Charles River Japan, Kanagawa, Japan)
was prepared in our laboratory. All plasma samples
were separated within 2 h after collection of blood
samples by using EDTA as an anticoagulant. The
plasma samples were obtained from all animals after
16 h of fasting. The plasma samples were immedi-
ately frozen and stored at −80 °C. The experimental
protocols for the animal procedures were approved
by the Ethics Review Committee for Animal Experi-
mentation of the National Institute of Health Sci-
ences (Tokyo, Japan).
Lipid extraction
Lipid extraction and measurement of lipid metabolites
by LC-MS was performed as reported previously [14, 15].
In brief, lipid metabolites were extracted from 90 μL of
plasma for humans and animal species, by using the Bligh
and Dyer method with a few modifications. Briefly, plasma
was mixed with 3.71 mL of chloroform/methanol/20 mM
Kpi (1:2:0.8) for 5 min. 12:0–12:0 phosphatidylethanol-
amine (12:0–12:0 PE, Avanti, Polar Lipids, Inc., Alabaster,
AL) was used as the internal standard (IS). Next, 1 mL
each of chloroform and 20 mM Kpi was added, mixed for
5 min, and centrifuged at 1000 × g for 10 min. After dis-
carding upper layers, 3.2 mL of chloroform/methanol/
100 mM KCl (3:47:48) were added, mixed, and then
centrifuged at 1000 × g for 10 min to separate the lower
organic layer. The lower organic layers were supplied
to non-targeted lipidomic analysis.
Non-targeted lipidomics
The lower organic layers were used for the measurement
of PLs, SLs, and neutral lipids (NLs) using LC-time of
flight (TOF)-MS (Acquity UPLC system-LCT Premier
XE; Waters, Milford, MA). The samples from each
group were randomized across the LC-TOF-MS meas-
urement. PLs and SLs were detected in the negative ion
mode, while NLs were detected in the positive ion mode.
Data obtained from LC-TOF-MS were processed using
the 2DICAL software (Mitsui Knowledge Industry,
Tokyo, Japan). The extracted ion peaks were analyzed
Table 1 Circulating lipid metabolites identified by non-targeted
lipidomic analysis of each mammal
Lipid types Ion mode Lipid classes Number















lysoPC lysophosphatidylcholine, lysoPE lysophosphatidylethanolamine, PC
phosphatidylcholine, ePC ether-type phosphatidylcholine, PE phosphatidyletha-
nolamine, ePE ether-type phosphatidylethanolamine, PI phosphatidylinositol,
SM sphingomyelin, Cer ceramide, HexCer hexosylceramide, DG diacylglycerol,
Ch/ChE cholesterol/cholesteryl ester, CoQ coenzyme Q
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for identifying lipid metabolites by comparison of the
ion features including RT, m/z, preferred adducts, and
in-source fragments of the experimental samples with
those of our reference library of lipid metabolite entries.
The levels of the identified lipid metabolites were normal-
ized to those of IS. If more than two lipid species possessed
the same chemical formula, alphabetical letters were put
after each lipid molecule class to distinguish them from
each other.
Statistical analysis
The statistical analyses were performed using Welch’s
t-test with Bonferroni correction for the comparison of
metabolite levels among humans and different animal
species. Differences with p values less than 0.05 were
considered statistically significant.
Results and discussion
Lipidomic analysis of human and preclinical animal plasma
To investigate differences in circulating lipid profiles
among humans and three animals often used in preclinical
studies, we performed a non-targeted lipidomic analysis
using plasma samples obtained from each mammal. To
maintain experimental quality throughout extraction and
measurement, the coefficient of variation for the IS was
calculated as 11.7 %. In total, we identified 206 lipid
metabolites consisting of 122 PLs, 39 SLs, and 45 NLs
(Table 1 and Additional file 1: Table S1). Of the 206 identi-
fied lipid metabolites in all the mammals, the levels of
163, 166, and 151 metabolites were significantly different
in mice, rats, and rabbits, respectively, when compared
with the levels of those metabolites in humans (Fig. 1).
As shown in Fig. 1a, the levels of many phosphatidyl-
cholines (PCs) were significantly lower in the three ani-
mals than in humans, although relatively longer and
highly unsaturated PCs showed significantly higher levels
in mice than in humans. The levels of many phosphatidyl-
ethanolamines (PEs) were significantly lower in rodents
than in humans, while those of many PEs were signifi-
cantly higher in rabbits than in humans (Fig. 1d). Among
ether-type PCs and PEs (ePCs and ePEs), many metabo-
lites showed significantly lower levels in the three selected
animal models than in humans, with several exceptions in
mice (Fig. 1c and e). Phosphatidylinositols (PIs) showed
significantly higher levels in mice than in humans (Fig. 1g).
In contrast, the levels of many PIs were significantly lower
in rabbits than in humans. As shown in Fig. 1m, the levels
of many ChEs were significantly different between
humans and the selected animal species, although the
differences varied in the three animal species.
Recently, lysoPCs and SLs have been proposed as
biomarker candidates for the prediction and evalu-
ation of diseased states and drug safety, respectively,
such acetaminophen-induced liver injury [9], drug-induced
phospholipidosis and β-cell dysfunction [12, 16] in pre-
clinical studies. In the present study, most of the 11
lysoPCs (9 in mice and 6 in rats) were present at sig-
nificantly higher levels in rodents than in humans
(Fig. 1b). On the other hand, most of the 39 SLs (33 in
mice, 36 in rats and 30 in rabbits) were present at
significantly lower levels in all the three animal species
which are often used in preclinical studies than in
humans, although Suls showed significant higher levels
in rabbits than in other mammals (Fig. 1h-k). These
results indicated that broad molecules of lysoPCs and
SLs show different levels in human and animal species.
Therefore, species differences should be carefully con-
sidered when these lipid molecules are selected as bio-
marker candidates identified in preclinical studies for
extrapolation and usage in clinical studies.
Lipid metabolites showing more than 10-fold difference
in their levels between humans and animal species
The extent of differences in the levels of lipid metabo-
lites between humans and animal species that are used
in preclinical studies seems to be the key problem for
the extrapolation of biomarker candidates identified in
preclinical studies into clinical studies. Because the
range of fold change for the reported lipid biomarkers
identified using animals species were approximately
0.5–8.0-fold [9, 12, 13, 16], the lipid metabolites that
exceeded this range might be unsuitable as biomarker
candidates in humans. We therefore focused on the
lipid metabolites that showed greater than 10-fold value
and significantly different levels in animal species as
compared to their levels in humans (Tables 2, 3, 4).
The numbers of these lipid metabolites were 19, 37,
and 12 for mice, rats, and rabbits, respectively.
(See figure on previous page.)
Fig. 1 Heat maps of lipid metabolites among humans and three animal species. The heat map with significantly different (p < 0.05) lipid metabolites
were generated using mean fold changes in the levels of metabolites calculated as ratios of each animal species to human. Vacant white cells indicate
metabolites that were detected, but their levels were not significantly different. (a) PC, (b) lysoPC, (c) ePC, (d) PE, (e) ePE, (f) lysoPE, (g) PI, (h) SM, (i) Cer,
(k) HexCer, (l) DG, (m) Ch/ChE and (n) CoQ. If more than two lipid species possessed the same chemical formula, alphabetical letters were put after
each lipid molecule class to distinguish them from each other (Additional file 1: Table S1). PC, phosphatidylcholine; lysoPC, lysophosphatidylcholine; ePC,
ether-type phosphatidylcholine; PE, phosphatidylethanolamine; lysoPE, lysophosphatidylethanolamine; ePE; ether-type phosphatidylethanolamine; PI,
phosphatidylinositol; SM, sphingomyelin; Cer, ceramide; HexCer, hexosylceramide; DG, diacylglycerol; Ch/ChE, cholesterol/cholesteryl ester;
CoQ, coenzyme Q
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Interestingly ChEs with PUFA, such as 23:6 and 24:6
ChE, showed markedly higher levels (179.7175- and
48.3842-fold, respectively) in mice than in humans
(Table 2). These large changes of the PUFA-containing
ChEs were also consistent with the results obtained in
rats, showing 13.9319-fold and 18.5058-fold changes for
23:6 and 24:6 ChE, respectively (Table 3). These results
indicated that the levels of circulating PUFA-containing
ChEs are higher in rodents than in humans. However,
the mechanism underlying the species-specific difference
in these levels remains unknown.
As shown in Table 3, 15 ether-type PLs, such as 36:3
ePCb and 36:3 ePE, were present in drastically lower
levels (less than 0.1-fold) in rats as compared to their
levels in humans (the range of fold changes; 0.0331-
0.0947). In addition, all other ether-type PLs, except 40:4
ePE, were significantly lower in rats than in humans
(Fig. 1c and e). Moreover, many ether-type PLs showed
significantly lower levels in mice than in humans (Fig. 1c
and e), although the ether-type PLs which showed less
than 0.1-fold change and significantly lower levels were
only found for 36:3 ePCb and 38:6 ePC (Table 2). These
observations suggested that circulating basal levels of
many ether-type PLs are lower in rodents than in
humans. The mechanism underlying this difference in
the levels of ether-type PLs in rodents remains unknown
and needs to be investigated in the future studies.
Rabbits are often used in preclinical studies in addition
to rodents. All three Suls showed more than 20-fold
higher levels in rabbits than in humans (Table 4). Suls
have been proposed as biomarkers for neurodegenerative
diseases such as Alzheimer’s disease [17] and multiple
sclerosis [18]. Therefore, when Suls are identified as bio-
marker candidates for disease states and drug responses
in rabbits, their extrapolation into human clinical trials
calls for extensive study and needs attention.
Table 3 Lipid metabolites that showed more than 10-fold and
significant differences between humans and rats
>10-fold <10-fold
Metabolite Fold Metabolite Fold
21:4 ChE 17.6192 34:3 PCb 0.0648
21:5 ChEa 12.2477 36:3 PCb 0.0827
22:4 ChE 20.3018 38:4 PCa 0.0844
23:6 ChE 13.9319 34:2 ePCa 0.0717




























If more than two lipid species possessed the same chemical formula,
alphabetical letters were put after each lipid molecule class to distinguish
them from each other (Additional file 1: Table S1)
ChE cholesteryl ester, PC phosphatidylcholine, ePC ether-type phosphatidylcho
line, PE phosphatidylethanolamine, ePE ether-type phosphatidylethanolamine,
SM sphingomyelin, HexCer hexosylceramide, DG diacylglycerol, CoQ
coenzyme Q
Table 2 Lipid metabolites that showed more than 10-fold and
significant differences between humans and mice
>10-fold <10-fold
Metabolite Fold Metabolite Fold
22:6 lysoPC 21.1692 36:3 ePCb 0.0887
21:4 ChE 47.2233 38:6 ePC 0.0973
21:5 ChEa 24.4064 43:2 SM 0.0648
21:5 ChEb 12.0447 34:1 di-HexCer 0.0293
22:6 ChE 17.7039 42:2 di-HexCer 0.0790
23:6 ChE 179.7175 34:1 DGa 0.0409
24:6 ChE 48.3842 34:2 DGa 0.0935
40:4 ePE 10.4272 14:1 ChE 0.0610
40:6 ePEa 11.1450 CoQ10 0.0899
42:6 ePE 18.4164
If more than two lipid species possessed the same chemical formula,
alphabetical letters were put after each lipid molecule class to distinguish
them from each other (Additional file 1: Table S1)
lysoPC lysophosphatidylcholine, ChE cholesteryl ester, ePE ether-type phospha
tidylethanolamine, ePC ether-type phosphatidylcholine, SM sphingomyelin,
HexCer hexosylceramide, DG diacylglycerol, CoQ coenzyme Q
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Conclusions
We compared the profiles of circulating lipid metabolites
between humans and three animal species often used in
preclinical studies by using a non-targeted lipidomics
approach. By comparing these profiles, we revealed that
some of circulating lipid metabolites were present at
markedly different levels between humans and animal
species. Our results therefore provide useful and funda-
mental information for selecting biomarker candidates
that might be identified in future preclinical studies for
their successful extrapolation into human clinical studies.
Additional file
Additional file 1: Table S1. Normalized peak height of
phosphoglycerolipids, sphingolipids, and neutral lipids in the plasma
of all the mammals. (XLSX 112 kb)
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If more than two lipid species possessed the same chemical formula,
alphabetical letters were put after each lipid molecule class to distinguish
them from each other (Additional file 1: Table S1)
Sul sulfatide, ePC ether-type PC, SM sphingomyelin, HexCer, hexosylceramide,
ChE cholesteryl ester
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